With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Amber Tong

Ever since its launch in 2020, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

With fresh $160M, Rayze­Bio plots sprint through the clin­ic for lead ra­dio­phar­ma­ceu­ti­cal pro­gram — build­ing on No­var­tis' suc­cess

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?